No recent analyst price targets found for SHJBF.
Latest News for SHJBF
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
The supplemental application for Toripalimab plus chemotherapy as perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC has been accepted by the NMPA.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SHJBF.
Senate Trading
No Senate trades found for SHJBF.
U.S. House Trading
No House trades found for SHJBF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.